Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

Market Cap	119.53B
Revenue (ttm)	236.54B
Net Income (ttm)	2.29B
Shares Out	23.91M
EPS (ttm)	95.99
PE Ratio	52.09
Forward PE	n/a
Dividend	50.00 (1.00%)
Ex-Dividend Date	Dec 27, 2024

Volume	12,947
Average Volume	22,221
Open	5,070.00
Previous Close	5,060.00
Day's Range	4,995.00 - 5,070.00
52-Week Range	4,755.00 - 7,500.00
Beta	1.12
RSI	53.53
Earnings Date	Aug 14, 2025

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 214390

Financial Performance

In 2024, Kyongbo Pharmaceutical's revenue was 238.56 billion, an increase of 10.26% compared to the previous year's 216.36 billion. Earnings were 4.64 billion, an increase of 55.98%.